Together, our study provides compelling evidence that BU peptide antagonises GRPR by competitively blocking GRP-induced receptor activation and downstream PI3K/Akt and MAPK/ERK signalling, thereby inducing apoptosis and suppressing tumour cell viability. Here, GRP is linked to neoplasm.